

## ABIVAX announces its financial calendar for 2018

**Paris, December 15<sup>th</sup> 2017 – (06:00pm CET)** - ABIVAX (Euronext Paris: FR0012333284 – ABVX), a biotechnology company harnessing the immune system to develop a functional cure for HIV and treatments for inflammatory/autoimmune diseases and cancer, today provides its planned financial calendar for 2018, which is set as follows:

Date*	Announcement
<b>Friday March 16, 2018</b>	Publication of 2017 Financial Statements
<b>Monday April 30, 2018</b>	Publication and Release of the 2017 Annual Financial Report
<b>Friday June 15, 2018</b>	Annual Shareholders Meeting
<b>Monday September 19, 2018</b>	Publication of Financial Statements as of June 30, 2018
<b>Friday September 28, 2018</b>	Publication and Release of 2018 Half Year Report

*\* Subject to modification. Press releases are distributed either before the financial markets opening, or after the closure*

All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company's website in the Investors' section ([www.abivax.com/en](http://www.abivax.com/en)).

### **About ABIVAX ([www.abivax.com](http://www.abivax.com))**

**ABIVAX** is an innovative biotechnology company targeting the immune system to develop novel treatments for viral and inflammatory diseases as well as cancer. ABIVAX leverages three technology platforms for drug discovery: an antiviral, an immune enhancement, and a polyclonal antibody platform. ABX464, its most advanced compound, is currently in Phase 2 clinical trials for providing a sustained viral remission or functional cure for patients with HIV/AIDS. It is a first-in-class oral small antiviral molecule which blocks HIV replication through a unique mechanism of action and also has a strong anti-inflammatory effect, which is currently explored through a phase 2a proof-of-concept clinical trial in ulcerative colitis. In addition, ABIVAX is advancing a clinical stage immune enhancer for the treatment of cancer as well as multiple preclinical candidates against additional viral targets (e.g., Respiratory Syncytial Virus (RSV), Influenza and Dengue), and several of these compounds are planned to enter clinical development within the next 18 months. ABIVAX is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX).

More information on the company is available at [www.abivax.com](http://www.abivax.com).

Follow us on Twitter @ABIVAX\_



## Contacts

### ABIVAX

#### Finance

Didier Blondel

[didier.blondel@abivax.com](mailto:didier.blondel@abivax.com)

+33 1 53 83 08 41

#### US Media

#### LifeSci Public Relations

Matt Middleman, M.D.

[matt@lifescipublicrelations.com](mailto:matt@lifescipublicrelations.com)

+1 646 627 8384

### Communication Agency

#### ALIZE RP

Caroline Carmagnol/Aurore Gangloff

[abivax@alizerp.com](mailto:abivax@alizerp.com)

+33 6 64 18 99 59 / +33 1 44 54 36 65

### Investors

#### LifeSci Advisors

Chris Maggos

[chris@lifesciadvisors.com](mailto:chris@lifesciadvisors.com)

+41 79 367 6254